TIDMGENF
RNS Number : 9662Y
Genflow Biosciences PLC
11 May 2023
11 May 2023
Genflow Biosciences Plc
("Genflow" or "the Company")
Appointment and Internal Restructure
In light of the ongoing progress being achieved by Genflow, the
Board of Directors has proactively decided to restructure both
itself and the Company's Scientific Advisory Board ("SAB"). This
step has been taken to align with the Company's current objectives
and priorities in the US, including the OTCQB application
previously announced, as outlined below:
(a) Tamara Joseph, the Company's US-based Non-Executive
Director, has been promoted to Chairperson of the Board. Her
experience in financing, coupled with her familiarity with the US
public markets, will play a crucial role going forward.
Tamara has an impressive track record in public and private
financings, having supported Nasdaq financings in excess of $800m.
Her expertise in the field of finance is further strengthened by
her academic credentials, which include a JD from the University of
Michigan Law School and LLM degrees from the College of Europe in
Belgium and the University of Paris.
Having served as an adviser to the boards of five US publicly
traded biotechs, Tamara has demonstrated a strong ability to lead
companies. Her promotion is a recognition of her expertise and
strengthens the Company's links with the US market.
Yassine Bendiabdallah , will remain a key member of the Board
and will continue to act as a Non-Executive Director.
(b) Vera Gorbunova PhD, has been promoted to Chairperson of the
SAB. Dr Gorbunova is an endowed Professor of Biology at the
University of Rochester, New York, and Co-Director of the Rochester
Ageing Research Center, where her research focuses on the
mechanisms of longevity and genome stability, as well as studies on
exceptionally long-lived mammals.
Throughout her career, Dr. Gorbunova has received numerous
awards for her work, including from the Ellison Medical Foundation,
the Glenn Foundation, the American Federation for Ageing Research,
and the National Institutes of Health. Her research has also been
recognized with the Cozzarelli Prize from PNAS, the prize for
research on ageing from ADPS/Alianz (France), the Prince Hitachi
Prize in Comparative Oncology (Japan), and the Davey Prize from
Wilmot Cancer Center.
As Chairperson of the SAB, Dr. Gorbunova's outstanding
contributions to the field of longevity and her invaluable insights
in this sector will be instrumental in guiding the Company's
scientific research. This appointment is a testament to her
expertise and achievements in the field.
Dr Eric Verdin will remain a key member of the SAB.
(c) Professor Dr Sven Francque is joining the SAB. Professor
Francque is a renowned expert in the field of nonalcoholic fatty
liver disease (NAFLD) and its advanced form, nonalcoholic
steatohepatitis (NASH).
He has a long-standing interest and expertise in NAFLD and NASH,
with research focusing on the vascular changes in steatosis and
their contribution to disease progression. Genflow stands to gain
significant value from Professor Francque's extensive knowledge of
NASH, particularly in identifying new targets and potential
therapies for the disease.
Moreover, Professor Francque's expertise in clinical research
and clinical trial design will be invaluable in the development of
clinical trial programs for the Company's novel therapeutics. His
membership on the SAB will play a vital role in shaping and
broadening the Company's strategy and direction, and his vast
experience will be integral to achieving the Company's goal of
improving the lives of patients with NAFLD and NASH.
Yassine Bendiabdallah, Director, commented: "We remain dedicated
to adapting and evolving in the ever-changing longevity space. Our
collective and individual agility gives us a significant advantage
over larger competitors and allows us to remain at the forefront of
this dynamic industry.
I am incredibly proud of the strong team we have in place, and
it's an honour to work alongside such esteemed leaders in this
field. Our commitment to innovation and our ability to navigate the
dynamic landscape of the longevity sector is central to our
continued success."
The information communicated in this announcement is inside
information for the purposes of Article 7 of Regulation
596/2014.
For further information please contact:
Genflow Biosciences Plc
Dr Eric Leire
Chief Executive Officer +32 477 495 881
-----------------
Clear Capital Markets
-----------------
Corporate Broker
Andrew Blaylock +44 203 869 6080
-----------------
About Genflow Biosciences
Genflow is a UK-based biotechnology company established in 2020.
The Company is developing gene therapies designed to target the
aging process and to reduce and delay the incidence of age-related
diseases. This will be done through novel therapeutics targeting
aging in humans by using adeno-associated virus ("AAV") vectors to
deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is
found in centenarians into cells.
Its mission is to increase our understanding of the factors that
control and impact lifespan. Genflow researches, develops, and
commercialises therapeutic solutions to lengthen health span, the
amount of time we live in good health, creating biological
interventions that enable longer and healthier lives. Genflow is
dedicated to the development and commercialisation of novel
therapeutics targeting aging in dogs and humans. By treating aging,
Genflow can contribute to a decrease in healthcare costs and lessen
the emotional and societal burden that comes with an aging
population.
To learn more visit www.genflowbio.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBBLFFXELBBBV
(END) Dow Jones Newswires
May 11, 2023 02:00 ET (06:00 GMT)
Genflow Biosciences (LSE:GENF)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Genflow Biosciences (LSE:GENF)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024